Tau accumulation in the brain is a pathologic hallmark of Alzheimer disease and other tauopathies. Quantitative visualization of tau pathology in humans can be a powerful method as a diagnostic aid and for monitoring potential therapeutic interventions. We established methods of PET quantification of tau pathology with 11 C-PBB3 (2-((1E,3E)-4-(6-( 11 C-methylamino)pyridin-3-yl)buta-1,3-dienyl) benzo [d]thiazol-6-ol), considering its radiometabolite entering the brain. Methods: Seven Alzheimer disease patients and 7 healthy subjects underwent dynamic 11 C-PBB3 PET scanning. Arterial blood was sampled to obtain the parent and metabolite input functions. Quantification of 11 C-PBB3 binding was performed using dual-input models that take the brain metabolite activity into consideration, traditional single-input models without such considerations, and the reference tissue model (MRTM O ) and standardized uptake value ratio (SUVR). The cerebellar cortex was used as the reference tissue for all methods. Results: The dual-input graphical models estimated binding parameter (BP 
Seni le plaques and neurofibrillary tangles are the 2 pathologic hallmarks of Alzheimer disease (AD). Senile plaques consist of extracellular b-amyloid (Ab) deposits (1, 2) . PET has been used for detecting Ab accumulations and also applied to monitor potential effects of Ab immunotherapies (3) (4) (5) . Neurofibrillary tangles consist of intraneuronal aggregates of hyperphosphorylated tau proteins (6) . Since the tau pathology in AD is closely related to the neural death and cognitive dysfunction along with the amyloid pathology (7, 8) , it is a promising therapeutic target for AD (9, 10) . The tau pathology is also known in other neurodegenerative disorders such as progressive supranuclear palsy and corticobasal degeneration (11, 12) . Thus, a reliable quantitative visualization of tau accumulation would be essential for accurate diagnosis and the development of disease-modifying drugs targeting tau in diverse neurologic diseases (13, 14) .
Recently, we developed a new radioligand, 11 C-PBB3 (2-((1E,3E)-4-(6-( 11 C-methylamino)pyridin-3-yl)buta-1,3-dienyl) benzo[d]thiazol-6-ol), for PET tau imaging (15) . Our in vitro data indicated that 11 C-PBB3 binds reversibly to neurofibrillary tau tangles with high affinity (K D 5 2.5 nM) and selectivity (50-fold selectivity over Ab deposits) (15) . Of the other recently reported tau radioligands including THK families (16) (17) (18) (19) and T80x (20, 21) , 11 C-PBB3 binds to tau lesions with a wide range of isoform compositions (15) . The regional standardized uptake value ratio (SUVR) of 11 C-PBB3 in our previous 11 C-PBB3 PET studies reflected the known pathologic tau distribution at various stages of AD (22) .
Our previous 11 C-PBB3 studies in humans and mice indicated that 11 C-PBB3 on intravenous administration is rapidly converted to a major radiometabolite in plasma, a significant amount of which has been shown to enter the mouse brain (23) . This radiometabolite is expected to enter the human brain, which may complicate quantitative PET data analysis. It is therefore important to examine whether simplified quantitative measures such as SUVR accurately reflect specific binding of 11 C-PBB3 to pathologic tau deposits.
The purpose of the present study was to establish methods of quantifying 11 C-PBB3 binding considering the entrance of its radiometabolites into the human brain. We used dual-input models (24, 25) that apply the unmetabolized parent and radiometabolite in the plasma as input functions. We found that the parameter SUVR minus 1 (SUVR-1) and the reference tissue model binding parameter (BP to criteria of the National Institute of Neurologic and Communicative Diseases and Stroke/Alzheimer Disease and Related Disorders Association (26) . The Clinical Dementia Rating scale (27) was 0.5 or 1 in AD patients and 0 in HCs. Mini-Mental State Examination scores (28) were 19.4 6 2.4 in AD patients and 28.4 6 2.2 in HCs. All HCs were free of major medical and neuropsychiatric illnesses. 11 C-labeled Pittsburgh compound B (3) PET scans were also obtained on the day of the 11 C-PBB3 PET studies, and all AD patients were positive and all HCs were negative for Ab. This study was approved by the Radiation Drug Safety Committee and the Institutional Review Board of National Institute of Radiologic Sciences of Japan. Written informed consent or assent was obtained from all subjects. The study was registered with University Hospital Medical Information Network Clinical Trials Registry (UMIN000009052).
PET Imaging
11 C-PBB3 was produced as previously described (15, 23) . After an intravenous injection of 11 C-PBB3 (399 6 45 MBq; specific activity, 88 6 32 GBq/mmol), 70-min dynamic PET scans were conducted using an ECAT Exact HR1 system (Siemens AG). PET images were reconstructed with a filtered backprojection method with corrections for attenuation and scatter. The dynamic scan consisted of 6 · 10 s, 3 · 20 s, 6 · 1 min, 4 · 3 min, and 10 · 5 min frames.
Measurement of 11 C-PBB3 in Plasma
Manual arterial blood samples were concurrently obtained 30 times with PET. Each blood sample was centrifuged, and the radioactivity concentrations in whole blood and plasma were measured. The plasma fractions of the parent and its radiometabolites were determined by high-performance liquid chromatography from 6 samples. Acetonitrile was added to each plasma sample, and the samples were then centrifuged and subjected to radio-high-performance liquid chromatography (mBondapak C18 column [Waters], 7.8 · 300 mm; acetonitrile/ ammonium formate mobile phase with gradient elutions 5 40/60, 52/ 48, 80/20, 80/20, 40/60, and 40/60 at 0, 6, 7, 8, 9 , and 15 min, respectively; flow rate, 6 mL/min). Two-exponential functions were used to interpolate the fraction of the parent and radiometabolites to obtain input functions.
Quantification Models
To quantify 11 C-PBB3 specific binding to tau, we used dual-input models that use both parent and metabolite input functions, singleinput models that use a parent-only input function, and the reference tissue model and SUVR-1 that do not require blood data.
Dual-Input Models. We estimated 11 C-PBB3 binding parameters BP Ã ND and BP P (namely specific distribution volume [V S ] (29)) in 2 ways using dual-input graphical analyses developed by Ichise et al. (24, 30) . This graphical model is derived from the dual-input compartment model (24, 25) . This graphical model has the following 2 operational equations, both of which allow estimation of BP Ã ND and BP P when the system reaches transient equilibrium between the brain and plasma compartments (t*).
where C P a ; C M a , and C b are the radioactivity concentrations of the plasma parent, radiometabolite, and brain, respectively. C
where d is the plasma metabolite/parent concentration ratio at equilibrium (Supplemental Appendix A; supplemental materials are available at http://jnm.snmjournals.org) (24) . In Equations 2 and 3, a P and a M represent the total distribution volumes of the parent (V 
Eq. 4
From Equation 2, BP Ã ND can also be calculated as follows:
Eq. 6
Here, we defined the parameter expressed by Equation 4 as BP Single-Input Models. For the graphical analysis with unmetabolized 11 C-PBB3 as an input function, Logan plots were applied (31) . For the compartment model analysis, the standard 2-tissue-compartment (2TC) model was applied (32) . BP ND and BP P values were calculated from total distribution volumes in the target and reference tissues.
Reference Tissue Model. Reference tissue BP Ã ND estimated without blood data is the (tissue ratio-1) at equilibrium and is theoretically 
PET Data Preparation
In our preliminary 11 C-PBB3 data analysis, the 2TC model with arterial data for small ROIs was unstable due to rapidly clearing parent input functions and overall low brain 11 C-PBB3 uptake. To improve the statistical quality of PET ROI data, we defined ROIs as follows (Supplemental Fig. 1 ): individual cerebral cortical masks were first created on segmented T1-weighted MR images using statistical parametric mapping (SPM12; Wellcome Trust Centre for Neuroimaging, U.K.). Then, for AD patients, we generated 3-4 cerebral cortical ROIs pooling all voxels of high (.0.3, high), medium (0.15-0.3, middle), low (0-0.15, low), and nonbinding (,0) BP Ã ND values on preliminarily generated MRTM O parametric images by applying coregistered cerebral cortical masks. These 4 sets of ROIs had a sample volume of 12 6 6, 50 6 27, 103 6 35, and 188 6 64 cm, respectively. For HCs, we created 1 large entire cortical ROI (440 6 34 cm), because cerebral cortical BP Ã ND was uniformly low. We used the cerebellar cortex as the reference tissue because there was negligible tau pathology in the postmortem AD cerebellum (34) . Cerebellar cortical ROIs were manually defined on the coregistered T1-weighted MR images (7.8 6 1.9 cm). All ROIs were further modified on the PET images to avoid high radioactivity spilling in from the adjacent venous sinuses. ROI time-activity curves were generated from the coregistered dynamic PET data. All image data analyses were performed in PMOD 3.6 (PMOD Technologies Ltd.).
Comparison Analysis
We compared BP Ã ND and SUVR-1 values among the different models, the main purpose of which was to examine how closely reference tissue BP Ã ND and SUVR-1 that use no blood data match corresponding BP Ã ND by dual-input models that use both plasma parent and metabolite data or single-input models BP ND that use only plasma parent data. These comparisons were performed by calculating Pearson correlation coefficients (r 2 ).
RESULTS

Time-Activity Curves
The brain 11 C-PBB3 time-activity curves quickly peaked within a few minutes of intravenous injection of 11 C-PBB3 (1 SUV in AD and 0.8 SUV in HC) (Figs. 1A and 1B) , and then washed out quickly initially and then slowly. Plasma parent timeactivity curves peaked quickly and decreased also quickly thereafter (Figs. 1C and 1D) . One major radiometabolite of 11 C-PBB3 appeared quickly in the plasma and slowly decreased thereafter, accounting for 90% of the total plasma radioactivity at 3 min (Supplemental Figs. 2A and 2B ).
C-PBB3 Binding Parameter Estimation
Dual-Input Models. Graphical plots (Eq. 1) with a combined (parent 1 radiometabolite) plasma input became linear early after the radioligand injection (Fig. 2) when both a and b could be considered constant (24) . a estimations were stable within 5%, with t* varying from 11 to 40 min, and we fixed the t* value to 11 min for all subjects. There was no significant difference in d estimates between AD patients (78 6 22) and HCs (88 6 28) Table 1 ).
Single-Input Models. The graphical analysis with the parentonly input did not allow stable estimation of total distribution volumes, because the graphical plots were not linear within the PET scanning time (i.e., t* could not be identified). The standard 2TC model with plasma parent as an input function was unstable in estimating total distribution volume in some cerebral cortical regions. The BP ND values were estimated in the rest of the regions but with large parameter estimation variations ranging from 0.03 to 5.03 and from 20.35 to 1.49 in the cerebral cortex of AD patients and HCs, respectively. The 2TC BP ND did not correlate well with the dual-input graphical BP Ã ND (r 2 5 0.04, Fig. 3A ). The 2TC BP P values also showed large parameter estimation variations ranging from 0.8 to 68 and from 28.6 to 31 in AD patients and HCs, respectively. Likewise, the 2TC BP P did not correlate well with the dual-input graphical BP P (r 2 5 0.13, Fig. 3B ).
SUVR and Reference Tissue Model. The 3-dimensional plots of MRTM O were linear after t* (Supplemental (Fig. 6B) .
DISCUSSION
We established methods for quantification of tau pathology in the human brain using 11 C-PBB3. The dual-input graphical models with an assumption of radiometabolites entering brain accurately estimated specific binding parameter BP Significant amounts of the major radiometabolite of 11 C-PBB3 were found to enter the mouse brain (30% of radioactivity in the brain 5 min after injection) (23) . In the human blood, 11 C-PBB3 was also rapidly metabolized, and a major radiometabolite identical to that observed in mice was produced, and this metabolite is very likely to enter the brain, although it is more hydrophilic than 11 C-PBB3. We recently identified the chemical structure of this radiometabolite, and we are trying to synthesize it to measure its binding affinity for tau (H. Hashimoto et al., unpublished data, 2015) . We assumed in our data analysis that this radiometabolite has no significant affinity for tau. However, if the backbone structure of 11 C-PBB3 as a b-sheet ligand is preserved in the metabolic conversion, it may also bind to tau. Nevertheless, current BP Ã ND by dual-input graphical analysis and MRTM O can be also shown to be directly proportional to B avail (Supplemental Appendix B).
In the present study, the dual-input graphical analysis with a combined plasma input allowed robust estimation of BP We also applied dual-input compartment analysis (24, 25) . However, unlike the situation previously reported for 123 I-epidepride (24, 25) , this analysis for 11 C-PBB3 was unstable. The reason for this is that the model estimates 6 microparameters with a rapidly decreasing parent input as 1 of the 2 inputs as opposed to the graphical analysis estimating only macroparameters (V's). However, we were able to show that, by providing the values estimated by the graphical analysis, the dual-input compartment model fairly well described measured time-activity curve data (Supplemental Figs. 7A and 7B ). We applied the Logan plot to the predicted target brain time-activity curve due to the parent and found the plot was linear after t* 5 11 min (Supplemental Fig. 7C ), indicating that parent components of time-activity curves reach transient equilibrium and 11 C-PBB3 binding is reversible.
Meanwhile, the conventional 4-parameter 2TC model with a parent input alone, assuming no metabolites entering the brain, was also unstable in estimating microparameters. With V ND constrained to that of the cerebellar cortex, the macroparameter, BP ND , could be estimated albeit with a large estimation variability. However, these BP ND values did not match the BP In the cerebral cortex of HCs and nonbinding regions of AD patients, BP Ã ND was slightly negative. This result is attributable to the fact that the nondisplaceable distribution volumes in the cerebellar cortex (V P ND 1 dV M ND ) of both HCs and AD patients (16.7 6 4.7 in HCs and 16.9 6 2.6 in AD patients with no differences between the 2 groups) were slightly larger than those in the cerebral cortex of HCs (14.8 6 5.0) and nonbinding regions of AD patients (14.3 6 2.0). The exact reason for these regional differences in the nonspecific binding of 11 C-PBB3 is unclear at present. However, higher nonspecific binding or the presence of specific binding in the reference tissue theoretically does not violate the use of the reference tissue models when fitting is adequate (35) .
The variability of BP ND estimations by MRTM O is known to be small compared with other reference tissue models (33 Fig. 6 ), suggesting that the underestimation due to data noise is minimal, because the BP degree of the 11 C-PBB3 metabolisms, and therefore BP Ã ND may require a larger effect size for group comparisons. On the other hand, BP P should not suffer from this intersubject variation, but due to its quick metabolism, regular metabolite analysis of 11 C-PBB3 is not practical for the estimation of BP P .
We selected SUVR-1 at 30-50 min when specific-binding timeactivity curves become relatively flat (Supplemental Fig. 8 ). SUVR-1 can be practically obtained by a static PET scan initiated at a fixed time point after 11 C-PBB3 injections. By contrast, the reference tissue BP Ã ND estimation requires dynamic PET data, but the advantage of the reference tissue BP Ã ND estimation is its independence of cerebral blood flow or the systemic clearance of the radioligand. BP Ã ND therefore should be more suited for long-term longitudinal studies (36) .
CONCLUSION
We have established methods for quantification of tau pathology in the human brain using 11 C-PBB3. The BP Ã ND determined by dual-input graphical analysis models is consistent with the reference tissue BP Ã ND and SUVR-1, suggesting that these parameters can accurately quantify target tau deposits notwithstanding the entry of radiometabolites into the brain. MRTM O is suitable quantification for 11 C-PBB3 without blood data when a patient can be stably scanned for 60 min. If the motion of the patient hampers the dynamic data, SUVR-1 30-50 min can be used as an alternative method. 11 C-PBB3 thus appears an adequate radioligand for PET imaging of tau pathology. 
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